Earnings Call · Q4 FY2025·2026-03-30

Q4 25EPS -3.98%·Rev n/aQ3 25EPS -26.42%·Rev n/aQ2 25EPS +7.41%·Rev n/aQ1 25EPS -70.00%·Rev n/a⚠ consensus missing

Bicara Therapeutics Inc. BCAX

Rachel Frank — Unknown

Claire Mazumdar Clemon — Chief Executive Officer

Ryan Cohlhepp — Unknown

Ivan Hyep — Chief Financial Officer

−4.1%1d on move date−3.5% vs SPY3d+0.5%5d+5.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more BCAX calls or request research access.

More BCAX calls Browse calls Request research access